Targeting bacterial surface structures to fight antibiotic resistance

Bacteriology Core

NIH-funded research Scripps Research Institute, the · NIH-11082425

This study is working on creating special antibodies that can help your body fight off tough infections caused by bacteria that don't respond to regular antibiotics, like some strains of Staphylococcus aureus and Neisseria gonorrhoeae, with the hope of offering better treatment options for patients dealing with these stubborn infections.

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionScripps Research Institute, the NIH-funded
Lab location1 site (La Jolla, United States)
Project IDNIH-11082425 on NIH RePORTER

What this research studies

This research focuses on developing antibodies that specifically target glycans on the surface of harmful bacteria, such as antibiotic-resistant strains of Staphylococcus aureus and Neisseria gonorrhoeae. By creating these targeted antibodies, the research aims to enhance the body's ability to combat infections caused by these resistant pathogens. The approach includes testing the effectiveness of these antibodies in laboratory assays and in animal models to determine their potential in treating serious bacterial infections. Patients may benefit from new treatment options that could be more effective against antibiotic-resistant infections.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria, particularly those with severe or recurrent infections.

Not a fit: Patients with infections caused by non-bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new antibody therapies that effectively treat infections caused by antibiotic-resistant bacteria.

How similar studies have performed: Previous research has shown promise in using targeted antibodies to combat bacterial infections, indicating that this approach could be effective.

Where this research is happening

La Jolla, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.